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Hirschsprung disease (HSCR) is a partially penetrant oligogenic birth defect that occurs when enteric nervous 
system (ENS) precursors fail to colonize the distal bowel during early pregnancy. Genetic defects underlie 
HSCR, but much of the variability in the occurrence and severity of the birth defect remain unexplained. We 
hypothesized that nongenetic factors might contribute to disease development. Here we found that mycophe-
nolate, an inhibitor of de novo guanine nucleotide biosynthesis, and 8 other drugs identified in a zebrafish 
screen impaired ENS development. In mice, mycophenolate treatment selectively impaired ENS precursor 
proliferation, delayed precursor migration, and induced bowel aganglionosis. In 2 different mouse models 
of HSCR, addition of mycophenolate increased the penetrance and severity of Hirschsprung-like pathology. 
Mycophenolate treatment also reduced ENS precursor migration as well as lamellipodia formation, prolif-
eration, and survival in cultured enteric neural crest–derived cells. Using X-inactivation mosaicism for the 
purine salvage gene Hprt, we found that reduced ENS precursor proliferation most likely causes mycopheno-
late-induced migration defects and aganglionosis. To the best of our knowledge, mycophenolate is the first 
medicine identified that causes major ENS malformations and Hirschsprung-like pathology in a mammalian 
model. These studies demonstrate a critical role for de novo guanine nucleotide biosynthesis in ENS develop-
ment and suggest that some cases of HSCR may be preventable.
Introduction
Hirschsprung disease (HSCR) is a common birth defect (1 in 5,000 
incidence) in which the enteric nervous system (ENS) is missing 
from distal bowel (aganglionosis). Because the ENS controls 
intestinal motility, HSCR causes severe constipation, abdominal 
distension, bilious vomiting, growth failure, and life-threatening 
infection (1). Survival requires surgical excision of aganglionic 
bowel. After surgery, however, enterocolitis (i.e., bowel inflamma-
tion) occurs commonly (35% incidence), and approximately 5% of 
affected children still die from HSCR. Infrequently, long-segment 
HSCR necessitates intravenous nutrition, with accompanying 
life-threatening infections. Most children with HSCR (80%) have 
only a short segment of aganglionosis, which suggests that slightly 
enhanced bowel colonization by ENS precursors could prevent 
disease. New strategies are needed to enhance bowel colonization 
by ENS precursors and to reduce HSCR occurrence.
While HSCR undoubtedly requires genetic defects (2), almost 
all predisposing mutations have partial penetrance and variable 
expressivity. For example, inactivating RET mutations occur in 
15%–20% of sporadic and 50% of familial HSCR, but only about 
half of children with inactivating RET mutations have HSCR (2). 
Genetic interactions also influence HSCR risk (3–6); however, 
much variability in occurrence and severity of HSCR and other 
human birth defects remains unexplained. We hypothesized that 
nongenetic factors might affect HSCR occurrence. If so, then some 
cases of HSCR might be preventable by changes in prenatal care.
HSCR is caused by failure of distal bowel colonization by enteric 
neural crest–derived cells (ENCDCs) during weeks 4–7 of human 
gestation (7–9). Normally, ENCDCs proliferate vigorously and 
migrate rostrocaudally to colonize the entire intestine. A similar 
process occurs in mice from E9.5 to E13.5 and in zebrafish from 
36 to 96 hours post fertilization (hpf). Many genes (7, 10) in addi-
tion to RET are needed for ENS development, including SOX10, 
PHOX2B, EDNRB, EDN3, GDNF, intracellular signaling molecules 
(11, 12), cytoskeletal components (13, 14), and adhesion proteins 
(15–17). 30% of children with HSCR have additional birth defects, 
and at least 30 genetic syndromes are HSCR associated (2). The 
diverse molecular mechanisms supporting ENS development sug-
gest that many nongenetic factors could influence ENCDC bowel 
colonization and HSCR occurrence by modifying the activity or 
abundance of needed molecules. Furthermore, chemical perturba-
tion of the developing ENS may identify new pathways involved in 
ENCDC migration, self renewal, proliferation, or survival.
In order to identify medicines that might increase HSCR risk, 
gain new insight into HSCR genetics, and identify new modulators 
of ENS developmental biology, we conducted a zebrafish chemical 
screen. Here we show that mycophenolic acid (MPA), a commonly 
used immunosuppressant, caused ENS developmental defects in 
fish and impaired ENCDC colonization of the bowel in mice via 
inhibition of inosine monophosphate dehydrogenase (IMPDH), 
the rate-limiting enzyme in de novo GMP synthesis. Guanine 
nucleotides are essential for DNA replication and transcription 
and for >200 GTP-dependent proteins. Our findings suggested 
that reduced ENCDC proliferation after GTP depletion is the pri-
mary cause of MPA-induced bowel aganglionosis (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI69781DS1) and showed that IMPDH inhibition 
greatly increased the penetrance and severity of genetic defects 
affecting the ENS. These studies reinforce the central role of 
ENCDC proliferation in bowel colonization and raise the intrigu-
ing possibility that drugs, nutritional deficiencies, or gene poly-
morphisms that reduce cell proliferation during early pregnancy 
may increase HSCR occurrence.
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Results
Medications that inhibit ENS development. Zebrafish were treated with 
1,508 individual drugs from the Johns Hopkins Clinical Com-
pound Library (Supplemental Table 1 and ref. 18) for the entire 
duration of ENCDC colonization of the bowel (34–96 hpf). Using 
HuC/HuD (also known as Elavl3/4) immunohistochemistry to 
visualize neurons (19), we identified 9 compounds that consistent-
ly impaired ENS development, were systemically administered, 
and were not overtly toxic at doses affecting the ENS (Table 1). 
Dose-response studies permitted determination of median toxic 
dose (TD50) for ENS defects for these drugs. We analyzed MPA 
in more detail because it dramatically impaired fish ENS devel-
opment (Figure 1, A–C), is commonly used in humans, has a 
well-understood molecular mechanism, and has a TD50 within 
human therapeutic levels (20).
MPA impaired mammalian ENS development. MPA inhibits 
IMPDH, a protein detected in all E10.5–E12.5 bowel cells (Supple-
mental Figure 2) that is slightly more abundant in ENCDCs than 
in neighboring mesenchyme. To determine whether MPA impairs 
mouse ENS development, we injected pregnant dams with MPA 
daily from E10.5 through E12.5 and analyzed fetal bowel at E13.5. 
Since we expected MPA metabolism and effects to vary depend-
ing on genetic background, we used both the outbred CF1 strain, 
due to its high fertility and large litters, and the C57BL/6 stan-
dard laboratory strain (referred to herein as B6; see Methods for all 
complete strain names). CF1 fetuses tolerated 100 mg/kg/d (36% 
of adult human therapeutic dose, allometrically scaled to mice; 
ref. 21), but no B6 fetuses survived doses exceeding 25 mg/kg/d. 
In both strains, MPA caused dose-dependent reductions in the 
extent of ENCDC colonization of the bowel (Figure 1, D and E), 
as indicated by the extent of TuJ1+ neurites in the colon. While we 
have previously demonstrated that the caudal extent of TuJ1 reac-
tivity indicates the position of the ENCDC wavefront (12), these 
structures might not be tightly associated after MPA treatment. To 
directly assess the position of the wavefront, we mated B6 females 
to Wnt1-Cre Rosa26EYFP/EYFP males, marking all neural crest–derived 
cells with enhanced yellow fluorescent protein (EYFP). We exam-
ined the position of the most distal staining in the bowel using 
EYFP, TuJ1, and SOX10 immunoreactivity. Both SOX10 and TuJ1 
reliably reflected the extent of bowel colonization seen with EYFP 
after control or MPA treatment (Supplemental Figure 3), confirm-
ing that MPA impaired ENCDC colonization (Figure 1F). While 
MPA treatment reduced fetal size and colon length (Supplemen-
tal Figure 3), it also increased the absolute length of uncolonized 
colon, suggesting a greater effect of MPA on ENS development 
than on colon growth.
MPA impaired development of cultured ENCDCs. MPA could reduce 
migration in vivo by direct effects on ENCDCs or indirect effects 
on other fetal cells. To study ENCDCs moving on an acellular, 
migration-permissive surface, we cultured E12.5 midgut slices 
on fibronectin (12). MPA drastically reduced RET+ cell migration 
out of bowel explants (Figure 2, A, B, and E) and reduced the per-
centage of migrating ENCDCs with lamellipodia (Figure 2, F–I). 
MPA also significantly reduced DNA synthesis (Figure 2, A, B, 
and D) and induced ENCDC apoptosis (Supplemental Figure 4). 
MPA did not, however, alter neurite growth in postmitotic enteric 
neurons (BrdU– TuJ1+) grown in low-density dissociated cell cul-
ture (Supplemental Figure 5 and ref. 22). To confirm that MPA 
effects were due to reduced guanine nucleotide levels, we treated 
cells with guanosine to restore GTP through the purine salvage 
pathway. Guanosine efficiently rescued MPA’s effects on ENCDC 
migration (Figure 2, C and E), DNA synthesis (Figure 2D), and 
lamellipodia (Figure 2, F and J), which indicated that the effects of 
MPA are caused by IMPDH inhibition.
MPA selectively reduced ENCDC DNA synthesis in vivo. To deliver 
MPA more consistently than drug injections permit, the prodrug 
mycophenolate mofetil (MMF) was given in drinking water at 
1 mg/ml, a dose that improves survival in a mouse lupus model 
(23). B6 females mated to Wnt1-Cre Rosa26EYFP/EYFP males were 
treated with MMF from E10.5 to E13.5 and injected with BrdU 
1 hour prior to analysis. MMF decreased distal colon colonization 
by ENCDCs (Figure 3, A–D), recapitulating the effect of inject-
ed MPA. SOX10 and RET immunohistochemistry showed that 
neuronal differentiation in littermate fetuses was unaffected by 
MMF (Supplemental Figure 6, A–C). Since MPA might affect tran-
scription of mesenchyme-derived signals required for coloniza-
tion of the bowel, we measured Gdnf, Edn3, and Ece1 mRNA levels 
in E13.5 bowel using quantitative RT-PCR (qRT-PCR), but found 
no differences (Supplemental Figure 6D). In contrast to our in 
vitro data, cleaved caspase-3+ cells were rare in both ENCDCs and 
surrounding mesenchyme after MMF treatment (Supplemen-
tal Figure 7), but were readily detected in limb bud interdigital 
web. These results agree with recent studies that showed low but 
detectable rates of nuclear fragmentation (24) and cleaved cas-
pase-3 (25) reactivity in WT ENCDCs. While ENCDCs also can die 
through unconventional, caspase-independent processes in cir-
cumstances such as partial loss of RET expression (26), ENCDCs 
in culture readily undergo canonical apoptosis in response to 
Table 1
Compounds that inhibited ENS development in zebrafish
Compound TD50 in zebrafish ENS Cmax in mammals Indication Primary mechanism Target molecule
Artesunate 500 nM 1–3 μM Antimalarial Unknown Unknown
Benzbromarone 600 nM 6–8 μM Uricosuric Inhibits uric acid reabsorption URAT1
CinchophenA <100 nM Unknown Analgesic/antiinflammatoryB Possibly cyclooxygenase inhibition Unknown
Closantel 1.8 μM 82 μM AntihelminthicB Possibly mitochondrial uncoupling Unknown
Diclazuril 1 μM 5 μM CoccidiostatB Unknown Unknown
Flubendazole 2 μM 20 nM AntihelminthicB Inhibits microtubule assembly β-tubulinC
Lovastatin 0.4 μM 0.1 μM Antihyperlipidemic Inhibits cholesterol biosynthesis HMG-CoA reductase
MPA 1 μM 1–10 μM Immunosuppressant Inhibits de novo GMP synthesis IMPDH
Oxibendazole 200 nM 30 nM AntihelminthicB Inhibits microtubule assembly β-tubulinC
ADose-response studies not performed. BVeterinary. CInvertebrate.
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MPA, so we limited our examination of cell death to cleaved cas-
pase-3. Consistent with the effects of MPA on ENCDCs in cul-
ture, MMF reduced proliferation of colon ENCDCs. In contrast 
to its effects on ENCDCs, MMF actually increased the fraction 
of surrounding mesenchymal cells incorporating BrdU (Figure 3, 
E–G). Since this was unexpected, given the reduction in bowel size 
resulting from either MPA or MMF treatment (Supplemental Fig-
ure 3), we counted mitotic figures within these populations. The 
mitotic index was reduced within ENCDCs (Figure 3H), in con-
cordance with the reduced BrdU incorporation. In contrast to the 
BrdU results, however, the mitotic index in the mesenchyme was 
not increased, which indicates that MMF-treated mesenchymal 
cells entered S-phase, but did not divide at elevated rates. MMF 
therefore selectively reduced ENCDC proliferation and distal 
bowel colonization in vivo without increasing caspase-mediated 
apoptosis or altering neuronal differentiation.
MPA reduced ENCDC migration by reducing proliferation. Guanine 
nucleotide depletion must underlie MPA’s effects, because gua-
nosine rescues these effects in vitro. GTP is essential for DNA, 
RNA, and protein synthesis as well as for GTPases and many 
other proteins. To distinguish between primary effects of guanine 
nucleotide depletion on cell motility versus effects on ENCDC 
proliferation that secondarily reduce distal bowel colonization, we 
determined which effects of GTP depletion are cell autonomous. 
This is important because either reduced ENCDC proliferation or 
reduced cell intrinsic motility could prevent ENCDC migration 
into distal bowel (27). We used mice with a null mutation in the 
purine salvage gene Hprt (28), which is required for guanosine to 
rescue GTP depletion (29). Since Hprt is X-linked, 1 copy of the 
Hprt locus is randomly inactivated in each cell of a female. Thus, in 
all Hprt– male cells and in half of Hprt+/– female cells, HPRT protein 
is absent, and guanosine supplementation will not rescue GTP 
Figure 1
MPA inhibited ENS development in developing zebrafish and mouse. (A–C) Developing WT zebrafish were exposed to DMSO or MPA from 34 to 
96 hpf. (A) Larvae (N > 200) were immunostained for neuronal marker HuC/HuD. (B) Images in A merged with transmitted light. Filled arrowheads 
denote most caudal enteric neuron; open arrowheads denote vents. (C) Average uncolonized distal intestine, plotted vs. MPA dose and compared 
with control. (D–F) MPA exposure by maternal intraperitoneal injection from E10.5 to E12.5 impaired enteric neuron colonization of the mouse 
hindgut at E13.5 (D), as visualized by the neuronal marker TuJ1 (left side, ileocecal junction; dotted line, colon outline). The position within each 
E13.5 colon of the most caudal (E) neuronal process (marked by TuJ1) or (F) ENCDC cell body (ascertained by the lineage marker EYFP or by 
SOX10 staining in EYFP– littermates) in each E13.5 fetus is plotted for each MPA dose and mouse strain (thick lines denote mean). Scale bars: 
250 μm (A and B); 1 mm (D). ***P < 0.001, Kolmogorov-Smirnov test (C); ANOVA and t test (E and F).
Downloaded on April 20, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/69781
research article
4878 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 11   November 2013
depletion. Leveraging this system to determine which GTP deple-
tion effects are cell autonomous requires a cellular marker indicat-
ing which X chromosome is active. To achieve this, we mated male 
mice carrying an X-linked EGFP transgene (30) to Hprt+/– females, 
and E12.5 midgut explants were cultured with 5 μM MPA and 
100 μM guanosine, conditions that completely rescue MPA effects 
in WT explants. This mating resulted in 4 possible genotypes (Fig-
ure 4A). Of these, the female X-EGFP+, Hprt+/– genotype produces 
an embryo containing a mixture of cells with normal HPRT activ-
ity (EGFP+) and EGFP– cells with no HPRT activity. Therefore, each 
Figure 2
MPA reduced ENCDC migration, DNA synthesis, and lamellipodia in explant cultures. (A–C) Low-magnification confocal micrographs of 24-hour 
E12.5 midgut explant cultures immunostained for RET and BrdU (explant at left of each image). Guanosine (Guo; C) completely reversed 
the proliferation and migration reduction caused by MPA (B). (D) Quantification of BrdU labeling index and (E) distance migrated by the RET-
expressing population after 16 and 24 hours in culture. (F) MPA reduced the percentage of cells with lamellipodia within the neural crest–derived 
cell population (stained with anti-p75NTR) most distant from the explant, an effect that was also reversed by guanosine. (G–J) Optical sections of 
p75NTR- and phalloidin-stained ENCDCs demonstrated the changes in cell shape associated with MPA treatment. Filled and open arrowheads 
denote ENCDCs with and without lamellipodium, respectively. Insets show details of ENCDCs at the leading edge (enlarged ×1.8). Scale bars: 
250 μm (A–C); 50 μm (G–J). *P < 0.05, **P < 0.01, ***P < 0.001, repeated-measures ANOVA (D and E); ANOVA (F).
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explant from X-EGFP+, Hprt+/– fetuses contains a mixture of gua-
nosine-rescuable ENCDCs (EGFP+) and EGFP– cells that cannot 
convert guanosine to GMP, GTP, or dGTP. The other 3 genotypes 
served as controls. As expected, MPA- and guanosine-treated male 
(Hprt–/Y) explants had much less migration, less BrdU incorpora-
tion, and fewer lamellipodia than WT explants (Figure 4, D, F, and 
H), which confirmed that HPRT is required for guanosine rescue. 
In female WT explants, ENCDCs incorporated BrdU equally with-
in EGFP+ and EGFP– populations, as expected, whereas EGFP– cells 
in female X-EGFP+, Hprt+/– cultures incorporated very little BrdU 
compared with neighboring EGFP+ cells (Figure 4, B, C, and E). 
These observations confirmed that DNA synthesis is cell autono-
mous with respect to GTP depletion and that guanine nucleotides 
are inefficiently transferred from rescued WT to mutant cells.
Unexpectedly, the overall migration from Hprt+/– explants was 
equivalent to WT levels (Figure 4F). Moreover, despite absent BrdU 
incorporation, within Hprt+/– cultures, HPRT-deficient ENCDCs 
(EGFP–) migrated indistinguishably from neighboring HPRT-
expressing EGFP+ cells (Figure 4G). Furthermore, consistent 
with migration competence, the proportion of EGFP– ENCDCs 
with lamellipodia in Hprt+/– cultures was not reduced (Figure 4I). 
Thus, while DNA synthesis, cell migration, and lamellipodia were 
all affected by GTP depletion and required HPRT for guanosine 
rescue, only effects on DNA synthesis were cell autonomous with 
respect to GTP pools. ENCDCs with adequate GTP fully rescued 
the ability of adjacent GTP-depleted ENCDCs to migrate in cul-
ture. Consistent with these results, time-lapse imaging of isolated 
ENCDCs confirmed that MPA did not reduce cell motility. How-
ever, in explant cultures where dense clusters of ENCDCs migrate 
outward, time-lapse imaging confirmed slower migration of MPA-
treated ENCDCs (Supplemental Figure 8). Because ENCDC prolif-
eration also drives migration in vivo (27), these data suggest that 
the primary defect that causes HSCR-like delays in ENCDC migra-
tion after MPA/MMF treatment is reduced cell proliferation that 
secondarily reduces ENCDC colonization of distal bowel.
MMF increased penetrance and extent of aganglionosis. MPA is tera-
togenic (31) in humans, and some MPA-associated malforma-
tions are plausibly due to defective neural crest–derived cell devel-
opment (32). However, aganglionosis has not been described in 
MPA-exposed children or animals. We hypothesized that MPA’s 
effects on perinatal ENS structure might be more dramatic when 
combined with predisposing but incompletely penetrant muta-
Figure 3
MMF treatment reduces ENCDC migration and DNA synthesis in vivo. (A–D) Oral treatment of pregnant B6 dams with MMF from E10.5 to 
E13.5 reduced the colonization of the hindgut at E13.5. Shown are stitched maximum-intensity projections of untreated (A), mildly affected 
(B), and severely affected (C) fetal colons with EYFP-marked ENCDCs, demonstrating MMF’s inhibitory effect on ENCDC wavefront migra-
tion in vivo. Dotted lines denote outline of bowel. (D) The position within each E13.5 colon of the most caudal ENCDC cell body (ascertained 
by EYFP or by SOX10 staining in EYFP– littermates) is plotted for each treatment (thick lines denote mean). (E and F) 8-μm-thick maximum-
intensity projections of EYFP- and BrdU-labeled E13.5 colons. (G) Counting of BrdU+ cells within the volumes in F demonstrated a reduced 
proportion of BrdU+ ENCDCs and an increased proportion of BrdU+ mesenchymal cells after MMF treatment. mes, non-ENCDC mesen-
chyme. (H) Counting of mitotic figures showed that the proportion of ENCDCs undergoing mitosis was reduced, while the mitotic index of the 
mesenchyme was not significantly changed. Scale bars: 1 mm (A–C); 50 μm (E and F). *P < 0.05, **P < 0.01, Student’s t test (D); ANOVA (G); 
ANOVA on log-transformed values (H).
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Figure 4
Mosaic analysis reveals that effects of GTP depletion on migration and lamellipodia are non–cell autonomous. (A) Mating scheme, genotypes, 
HPRT and EGFP expression patterns, and GTP depletion status of each population when cultured in the presence of both MPA and guanosine. 
These conditions create mixed cultures of GTP-depleted and EGFP-marked, guanosine-rescued ENCDCs in X-EGFP+, Hprt+/– explants, allowing 
migration of individual GTP-depleted ENCDCs to be examined in the context of a field of rescued ENCDCs. (B–D) BrdU labeling revealed that 
guanosine rescued DNA synthesis in all ENCDCs in X-EGFP+, Hprt+/+ explants (B), but only rescued DNA synthesis within the HPRT-expressing 
ENCDCs marked by EGFP in X-EGFP+, Hprt+/– explants (C). As expected, guanosine failed to rescue DNA synthesis in Hprt–/Y ENCDCs (D). 
Filled arrowheads denote BrdU+EGFP+ double-positive ENCDCs; open arrowheads denote BrdU+GFP– ENCDCs. (E) Quantification of BrdU 
labeling in mosaic explants. (F) ENCDC migration out of explants was impaired in Hprt–/Y explants, as expected, but Hprt+/+ and Hprt+/– explants 
produced similar ENCDC migration distances. (G) Quantification of migration within the depleted (EGFP–) and rescued (EGFP+) populations of 
female Hprt+/– cells demonstrated that GTP-depleted cells did not migrate any less efficiently than rescued cells when surrounded by rescued 
cells. Similarly, while lamellipodia were reduced in Hprt–/Y explants (H), they were not reduced within the GTP-depleted ENCDC population in 
Hprt+/– explant cultures (I). Scale bar: 50 μm (B–D). ***P < 0.001, paired t test (E and I); ANOVA (F); Wilcoxon signed-rank test (G); t test (H).
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tions, and that HSCR might only be induced by MPA when such 
mutations are present. We therefore exposed the developing ENS 
of Sox10LacZ/+ mice to MPA. Sox10LacZ/+ mice have partially pen-
etrant aganglionosis and hypoganglionosis (33), modeling high-
penetrance HSCR in Waardenburg syndrome type IV. Explant cul-
tures of Sox10LacZ/+ E12.5 bowel had ENCDC migration and BrdU 
labeling that were equivalent to WT cultures under control condi-
tions. Importantly, MPA had similar effects on WT and Sox10LacZ/+ 
ENCDCs (Figure 5, A and B). Thus, in this short-term culture, 
MPA was not more toxic to mutant than to WT ENCDCs.
Next, we examined the interaction between MMF and Sox10 in 
vivo. Since Sox10 is haploinsufficient in the developing ENS, we 
crossed Sox10LacZ/+ males with B6 females (34) and treated them 
with MMF throughout prenatal ENS development (E7.5–E18.5). 
We attempted postnatal evaluation, but some MMF-treated pups 
had exencephaly and died immediately after birth. To avoid miss-
ing more severely affected animals, we harvested E18.5 fetuses. 
Occasionally, control dams delivered at E18.5, but ENS struc-
ture was similar to fetuses that had not delivered. Whole-mount 
immunohistochemistry for neuronal processes (TuJ1) and somata 
(HuC/HuD) demonstrated that Sox10 mutations and MMF indi-
vidually caused partially penetrant colonic hypoganglionosis and 
aganglionosis (Figure 5C). The combination of Sox10 mutation 
and MMF resulted in extensive bowel aganglionosis.
We next tested MPA on Ret+/– ENCDCs in culture, since RET is 
mutated in most human HSCR cases (2). Ret+/– mice, however, are 
never aganglionic or hypoganglionic (35). In contrast to Sox10LacZ/+ 
ENCDCs, Ret+/– ENCDCs did not migrate as efficiently as WT in cul-
ture, although BrdU labeling was unaffected by Ret genotype (Fig-
ure 5, D and E). MPA and Ret heterozygosity had additive effects on 
Figure 5
MMF treatment interacts with Ret and 
Sox10 mutations to increase penetrance 
and severity of HSCR-like pathology. 
(A and D) MPA treatment in 24-hour 
explant cultures revealed that neither 
Ret nor Sox10 heterozygosity affected 
BrdU incorporation. (B and E) In con-
trast, Ret but not Sox10 heterozygosity 
reduced ENCDC migration distance, 
and MPA treatment had an additive 
effect on ENCDC migration distance. 
Interaction terms were not statistically 
significant. (C and F) Pregnant dams 
were provided MMF or control PBS in 
drinking water, and the ENS was exam-
ined at E18.5 with neuronal fiber (TuJ1) 
and soma (HuC/HuD) markers. The 
position of the most caudal soma within 
the intestine is plotted as a dot, and the 
region of hypoganglionosis is plotted as 
a line. Mean positions of agangliono-
sis are denoted by black lines. Groups 
without abnormal fetuses are summa-
rized as 1 dot and number. Treatment 
with MMF from E7.5 to E18.5 resulted 
in hypoganglionosis and aganglionosis 
with genotype-dependant penetrance 
and severity. Treatment with MMF from 
E9.5 to E14.5 demonstrated genotype-
dependent reversal of the MMF-induced 
developmental delays. ***P < 0.001, 
2-way ANOVA (A, B, D, and E).
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distance migrated, consistent with known roles for RET in ENCDC 
migration (11, 36) and MPA’s primary effect on proliferation.
Since heterozygous null Ret mutations do not delay ENCDC 
colonization of fetal bowel (35) and only slightly alter adult ENS 
structure (37), we used a hypomorphic allele, Ret9, that causes par-
tially penetrant aganglionosis (38) to test the effects of MMF in 
vivo. Ret9/+ males were bred to Ret+/– females on a B6 background, 
and pregnant dams were treated with MMF from E7.5 to E18.5. We 
expected Ret9/– fetuses to have partially penetrant aganglionosis 
even without MMF (26), but found no 
aganglionosis and only 1 mouse with 
obvious hypoganglionosis (Figure 5F 
and Figure 6B). Other genotypes did 
not have detectable ENS abnormalities 
in control fetuses (Figure 5F and Figure 
6A). In contrast, 2 of 6 MMF-treated 
Ret+/+ fetuses had hypoganglionic or 
aganglionic colons (Figure 5F and Figure 
6C). Furthermore, MMF-treated Ret9/+ 
and Ret+/– fetuses had longer regions 
of aganglionic colon than WT fetuses 
(Figure 5F and Figure 6, D and E), 
demonstrating a synergistic effect. Strik-
ingly, all 8 MMF-treated Ret9/– fetuses 
had aganglionosis, often extending 
into small bowel (Figure 5F and Fig-
ure 6F). These findings are remarkable 
since the Ret9/– genotype closely mim-
ics heterozygous RET mutations that 
underlie more than 25% of human 
HSCR. Unlike human HSCR, however, 
sex did not affect the penetrance or the 
extent of ENS abnormalities in MMF-
treated Ret mutant mice.
Thus, MMF treatment from E7.5 
onward caused Hirschsprung-like agan-
glionosis that was significantly worse 
in genetically susceptible mice. We also 
tested the hypothesis that a more limit-
ed period of MMF exposure might cause 
permanent distal bowel aganglionosis. 
ENCDCs normally first enter the bowel 
at E9.5 (39) and reach the end of the 
colon by E13.5, but the colon becomes 
less permissive (40, 41) to ENCDC 
migration at E14.5. To determine 
whether MMF treatment during the critical period of ENCDC 
migration causes permanent or transient distal bowel agangliono-
sis, we switched dams carrying Sox10 and Ret litters from PBS to 
MMF for the interval from E9.5 to E14.5 and then allowed them 
to recover on PBS from E14.5 to E18.5. For Sox10 and Ret mat-
ings (Figure 5, C and F), the colons of all WT fetuses and inter-
mediate Ret genotype fetuses were completely colonized at E18.5, 
although 1 Sox10+/+ fetus had a hypoganglionic terminal colon. In 
contrast, aganglionosis was highly — although not universally — 
Figure 6
Representative maximum-intensity projec-
tions of myenteric plexus in the mid-small 
bowel, terminal ileum, proximal colon, and 
terminal colon from PBS-exposed WT (A) 
and Ret9/– (B) fetuses and MMF-treated 
Ret+/+ (C), Ret9/+ (D), Ret+/– (E), and Ret9/– 
(F) genotypes. PBS-exposed Ret9/– colon 
(B) displayed distal hypoganglionosis. 
(D–F) TuJ1 staining demonstrated thick 
nerve bundles in the aganglionic terminal 
colons and disorganized fibers in hypogan-
glionic regions. Scale bar: 100 μm (A–F).
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penetrant in Ret9/– fetuses treated with MMF from E9.5 to E14.5 
and was confined to the colon (Figure 5F). Furthermore, although 
the penetrance of aganglionosis in Sox10LacZ/+ fetuses treated with 
MMF from E9.5 to E18.5 was very similar to those treated from 
E7.5 to E18.5, the aganglionic segments were shorter on average if 
mice did not receive MMF before E9.5 and after E14.5. Collectively, 
these data suggest that significant ENCDC migration delays may 
be reversible, but the most susceptible genotypes lack the capacity 
to recover from transient MMF exposure.
It is important to note that the preceding data described colo-
nization of the bowel by ENCDCs derived from the vagal region 
of the neural crest. Interestingly, in mice with aganglionic bowel, 
the terminal third of the colon often had single neurons or iso-
lated clumps of neurons (<150 neurons per colon) associated with 
extrinsic nerve bundles and separated from vagal ENCDCs by long 
segments of bowel that were completely devoid of enteric neurons. 
These rare neurons are likely to arise from ENCDCs derived from 
the sacral region of the neural crest.
In addition to ENS defects, MMF-treated mice were small and 
had reduced bowel length (Supplemental Figure 9), exencephaly, 
and congenital heart defects. MMF-induced exencephaly was 
unaffected by genotype, but was only present in litters treated 
with MMF from E7.5 to E18.5 (Supplemental Table 2). Most heart 
defects occurred in Sox10 or Ret mutant fetuses in the E7.5–E18.5 
treatment group. Although the number of fetuses was small, 
the infrequent heart defects in MMF-treated control mice raises 
the possibility that Sox10 or Ret may have unappreciated roles in 
cardiac crest development that are only demonstrable with addi-
tional genetic or environmental insults. We also observed 6 MMF-
exposed fetuses with orofacial clefting and 3 with iris colobomas. 
These defects are similar to those previously reported in MMF-
exposed human infants (31).
Discussion
HSCR and other problems with ENS development are known to 
occur in individuals with many well-established genetic defects (2), 
which suggests that these disorders are not preventable. The gene 
defects and chromosomal anomalies that predispose to HSCR, 
however, are all partially penetrant and cause variable degrees of 
aganglionosis. This variation in phenotype in individuals who 
share the same underlying primary genetic defect is thought to 
occur, at least in part, because of interactions among genes needed 
for normal development. Our current data provide the first direct 
evidence that specific medicines affect ENS development, causing 
distal bowel aganglionosis in mice and fish that mimics human 
HSCR. In addition, our data showed dramatic gene-environment 
interactions. Importantly, these studies suggest the possibility that 
any factor that reduces ENCDC proliferation might increase the 
risk of distal bowel aganglionosis and that some cases of HSCR 
might be prevented by careful optimization of nongenetic risk fac-
tors during early pregnancy.
Most compounds found to inhibit distal bowel colonization by 
ENCDCs in fish lack obvious links to previously recognized ENS 
developmental pathways. Furthermore, because we tested only 1 
drug concentration, many additional medications are probably 
detrimental to the developing ENS. Besides MPA, 2 additional 
medications deserve comment. Lovastatin (Mevinolin; Merck) is 
a commonly used inhibitor of the rate-limiting step in de novo 
cholesterol biosynthesis (HMG-CoA reductase), which is interest-
ing because DHCR7 mutations disrupt the final step in cholesterol 
biosynthesis, causing HSCR as a component of Smith-Lemli-Opitz 
syndrome (42). Artesunate is a common malaria treatment that 
may increase ROS, and in Tcof1 mutant mice, additional oxidative 
stress delays ENCDC migration (43). These findings highlight the 
many complex pathways needed for ENCDC colonization of fetal 
bowel and the potential for diverse medicine classes to increase 
HSCR occurrence. This is especially important since families with 
1 child with HSCR have a 50- to 1,600-fold increased risk of having 
another child with the same life-threatening disease (2).
We investigated the immunosuppressant MPA in more detail, 
because it profoundly inhibited zebrafish ENS development at 
concentrations in the low human therapeutic range and represents 
the only drug identified associated with specific patterns of human 
birth defects (31). Despite inhibiting the ubiquitous process of 
GMP biosynthesis, some MPA-associated defects (e.g., cardiac 
defects, craniofacial defects, and coloboma) suggest that IMPDH 
inhibition disproportionately affects neural crest–derived cells 
(32). Interestingly, Drosophila IMPDH mutations (raspberry) cause 
mistargeting of photoreceptor axons (44), and MPA impairs cranial 
nerve development in rat embryos (45), demonstrating that defects 
in other neural cell types can be caused by abnormal purine metab-
olism. We are not aware of human ENS malformations reported 
after MPA or MMF exposure, but HSCR occurrence after exposure 
likely requires predisposing gene mutations. Here we showed that 
MPA caused dose-dependent distal ENS malformations in fish and 
mice, that MPA impaired ENCDC migration by depleting guanine 
nucleotides and reducing proliferation, and that mutations that 
model HSCR predisposition dramatically increased MMF’s terato-
genic effects on distal bowel colonization by ENCDCs.
The unique way in which the ENS develops may explain why 
ENCDCs are particularly sensitive to MPA/MMF. One possibility 
is that the relatively high rate of ENCDC proliferation compared 
with that of neighboring mesenchymal cells requires ENCDCs 
to synthesize guanine nucleotides more rapidly via IMPDH and 
the de novo synthesis pathway. The elevated levels of IMPDH 
observed in ENCDCs compared with adjacent cells are consistent 
with this hypothesis, as are the different effects of MMF in dif-
ferent cell types. As expected, MPA/MMF dramatically reduced 
BrdU incorporation and mitotic figures in ENCDCs. Remark-
ably, the effects of MPA/MMF in neighboring mesenchyme were 
more complex. In contrast to ENCDCs, a higher proportion of 
mesenchymal cells incorporated BrdU after MPA/MMF treat-
ment, but without a concomitant increase in mitoses. This might 
occur if MMF-treated mesenchymal cells have enough guanine 
nucleotide to enter S-phase, but have a prolonged period of DNA 
synthesis because of limited dGTP availability. Alternatively, gua-
nine nucleotide depletion could cause DNA damage, and the ele-
vated levels of BrdU incorporation reflect DNA repair. In any case, 
the effect on mammalian development of blocking a ubiquitous 
enzyme like IMPDH depends not only on how the drug affects the 
biology of individual cells, but also on how important that per-
turbation is for particular aspects of development. For example, 
proliferation is essential for ENCDCs to efficiently colonize the 
distal bowel (27). Reduced proliferation of other cell types might 
lead to smaller organs, but might not cause a structural defect, 
because proliferation is not essential for building that structure 
during the interval of drug exposure.
For our present studies, it was important to determine whether 
distal bowel aganglionosis in MPA/MMF-treated mice occurred 
because of reduced ENCDC proliferation (27) or whether deple-
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migrated an equal distance from gut explants in vitro, while the 
same Sox10 mutation impaired distal bowel colonization in vivo. 
This illustrates the importance of coupling in vitro and in vivo 
studies, since some defects will not be detected in the culture system 
currently in use. Differences that might be required to detect Sox10-
mediated defects include the much longer ENCDC migration time 
in vivo; the diverse set of factors affecting stem cell renewal, dif-
ferentiation, and migration; and the 3-dimensional environment 
in vivo that requires degradation of the extracellular matrix (53) 
and may engage alternate integrin or adherence protein signaling.
Collectively, our results provide the first strong evidence that 
medicines may affect ENS development and that potent gene-envi-
ronment interactions dramatically alter the risk of Hirschsprung-
like disease. Combined with our previous demonstration that vita-
min A deficiency increases Hirschsprung-like defects in concert 
with Ret mutations (12), the present work adds credibility to the 
hypothesis that unappreciated maternal nongenetic factors influ-
ence HSCR risk. Oral MMF may also be a valuable experimental 
tool to probe for genetic factors that predispose to ENS abnor-
malities, but are not severe enough to cause disease in the absence 
of additional defects.
Finally, these studies demonstrated a profound linkage among 
basic processes in cell metabolism and specific mammalian ENS 
developmental defects. This work supports the idea that any 
stressor that reduces the efficiency of ENCDC proliferation might 
increase HSCR occurrence and severity in children with predis-
posing mutations, even without altering “classical” ENS develop-
mental pathways. De novo purine biosynthesis, for example, is a 
multistep process for which enzymes require nicotinamide, folate, 
and vitamin B12. Focused investigation of clinically relevant anti-
metabolic stressors such as folate and B12 deficiency, antifolate 
medicines (e.g., trimethoprim and methotrexate), and other anti-
metabolites (e.g., azathioprine and 6-mercaptopurine) may iden-
tify immediate candidate interventions for reducing the incidence 
and severity of HSCR in genetically predisposed children. In paral-
lel with work in model systems, these studies suggest that human 
case-control epidemiologic investigation is appropriate and may 
uncover avoidable maternal exposures or health conditions that 
could reduce the risk of dangerous neural crest–dependent birth 
defects like HSCR.
Methods
Zebrafish. WT (AB) in vitro–fertilized embryos were treated (n ≥ 6 embryos 
per drug) with 10 μM drug and 1% DMSO in E3 Screening Media (54) 
from 34 to 96 hpf. 1% DMSO did not induce any defects, but may increase 
sensitivity, as 2% DMSO alone inhibited ENCDC migration. Distance from 
the most-caudal neuron (HuC/HuD+) to the bowel terminus was measured 
(n > 9,000 larvae) using a micrometer-calibrated eyepiece grid. Compounds 
were retested if mean uncolonized distance exceeded 125 μm, results were 
consistent between experiments, and the compound might cross the pla-
centa in mammals. Drugs causing death at 10 μM were retested at lower 
concentrations. Larvae with >100 μm of uncolonized bowel were consid-
ered to be affected for the TD50 calculations.
Mice. Vaginal plug day was considered E0.5. CF1 mice were from Charles 
River. B6 (C57BL/6J), C3Fe (C3HeBFe/J), 129X1 (129X1Sv/J), Wnt1-Cre 
(Tg[Wnt1-cre]11Rth; ref. 55), Rosa26EYFP (Gt(ROSA)26Sortm1(EYFP)Cos; ref. 56), 
and X-EGFP+ (Tg[CAG-EGFP]D4Nagy/J; ref. 30) mice were from the Jack-
son Laboratory. Other mouse strains and genetic backgrounds used were 
RetTGM (null allele Rettm1Jmi; ref. 57) on a B6 background, Sox10LacZ (null allele 
Sox10tm1Weg; ref. 33) on a C3Fe background (provided by M. Wegner, Fried-
tion of guanine nucleotides directly affected proteins needed for 
cell migration. In mesangial (46) and endothelial (47) cells, for 
example, MPA-mediated GTP depletion led to reduced levels of 
active (GTP-bound) Rho-family GTPases, including RAC1, a key 
regulator of the actin cytoskeleton. Our experiments, however, 
strongly suggested that MPA/MMF in the doses tested did not 
directly impair cell migration. Specifically, we found that ran-
dom motility of EYFP-labeled ENCDCs was unchanged by MPA 
(Supplemental Figure 8) when cells were cultured at a density 
that reduced cell-cell contact. Furthermore, using X-inactivation 
mosaicism, we deleted HPRT and depleted GTP in single ENCDCs 
that were surrounded by “normal” guanosine-rescued ENCDCs. 
In these cultures, the nonrescued ENCDCs remained BrdU–, 
excluding cell-to-cell transfer of any significant amount of gua-
nine nucleotide, but the GTP-depleted cells appeared to migrate 
essentially normally. Thus, with 2 different approaches, we dem-
onstrated that GTP-depleted ENCDCs can move at normal speeds, 
but fail to migrate effectively unless they are surrounded by adja-
cent normally proliferating ENCDCs. This result is conceptually 
related to the findings that Sox10 and Ednrb mutations have non–
cell-autonomous effects on ENCDC migration in aggregation chi-
meras (48, 49) and that proliferation inhibitors (27) or mechanical 
reduction of ENCDC density (35) can reduce ENCDC coloniza-
tion of cultured bowel. The molecular mechanisms that allow 
ENCDCs to sense and react to local ENCDC density or that con-
trol the unpredictable trajectories of individual ENCDCs remain 
unknown, although in other neural crest cells, both diffusible (50) 
and contact-mediated (51) signals are involved.
We therefore propose that reduced ENCDC proliferation par-
simoniously explains all other observed effects of MPA on the 
developing ENS. These results suggest the possibility that any 
condition that reduces ENCDC proliferation could increase the 
risk of HSCR. In addition to the risk of bowel aganglionosis in 
WT mice after MPA/MMF treatment, our data showed dramatic 
gene-environment interactions between MMF and either Sox10 or 
Ret mutations at term. MMF caused distal bowel aganglionosis 
when administered for the entire period of prenatal neural crest 
development (E7.5–E18.5) or during the period of ENCDC migra-
tion (E9.5–E14.5). Interestingly, ENCDCs were able to recover 
from a transient MMF-induced developmental delay in WT mice 
and in mice with “mild” Ret genotypes, but not in Sox10LacZ/+ or 
Ret9/– fetuses. Furthermore, MPA/MMF appeared to inhibit bowel 
colonization by both vagal and sacral neural crests. The sacral 
neural crest normally migrates proximally through terminal colon 
and forms 10%–20% of the distal colonic ENS (52). Although 
we observed isolated neurons in each aganglionic colon, sacral 
ENCDC derivatives, if present, are greatly diminished in number 
by MMF and/or the genetic lesions evaluated (i.e., less than 2% 
of anticipated sacral-derived neurons in this region). If the same 
phenomena occur in humans, then many potentially detrimental 
drug exposures will only cause HSCR in children with underlying 
predisposing mutations.
A few interesting differences were noted between in vivo ver-
sus explant culture results for Ret and Sox10 mutant animals. In 
vivo, Ret+/+ and Ret+/– ENCDCs migrate at the same rate through 
the colon (35), but we noted reduced migration of Ret+/– ENCDCs 
from cultured gut explants compared with WT cells. This may 
occur because the supraphysiologic level of GDNF used in culture 
saturates all RET receptors, whereas in vivo GDNF is limiting even 
in Ret+/– mice (37). In contrast, Sox10 mutant and WT ENCDCs 
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Alexa Fluor 488 donkey anti-goat, Alexa Fluor 594 donkey anti-goat, 
Alexa Fluor 647 goat anti-rabbit, or Alexa Fluor 647 donkey anti-goat; 
Invitrogen) incubation was for 1 hour at 25°C. When appropriate, DAPI 
(100 ng/ml) and/or Alexa Fluor 594– or Alexa Fluor 488–conjugated phal-
loidin (4 U/ml; Invitrogen) were added during secondary incubation.
An acid treatment step (4N HCl, 5 minutes, 25°C) was required for BrdU 
and RET staining and was performed after blocking (for TuJ1 costaining) 
or after antibody staining and a postfixation step (4% paraformaldehyde 
in PBS for 10 minutes) for costaining of other antigens. Samples were 
washed twice with TBS and blocked again between acid treatment and 
primary antibody incubation.
E18.5 mouse bowel anti-HuC/HuD staining required an alternate proce-
dure. Fixed samples were treated with 3% H2O2 in PBS (20 minutes at room 
temperature) before blocking in PBST (PBS, pH 7.4, with 1% Triton-X 100), 
10% normal donkey serum, 1% cold water fish skin gelatin, and 100 mM 
glycine. Endogenous biotin was blocked (Streptavidin/biotin blocking kit; 
Vector Labs) before an overnight 4°C incubation with biotin-XX–conjugated 
anti-HuC/HuD (400 ng/μl; Invitrogen; catalog no. A21272) in blocking solu-
tion. After 6 PBST washes, tissue was incubated with Alexa Fluor 594–con-
jugated streptavidin (1:2,000; Invitrogen) in PBST for 15 minutes at 37°C.
qRT-PCR. Intestines (from stomach to colon) were harvested from E13.5 
fetuses treated with PBS or MMF (E10.5–E13.5) and individually homog-
enized in 800 μl TRIzol (Invitrogen) by passage through a 26-gauge needle. 
RNA was isolated according to the manufacturer’s instructions, with 200 μg 
RNA-grade glycogen (Thermo Scientific) added as a carrier. 1 μg of each 
RNA sample was treated with RQ1 DNAse (Promega) in a total volume of 
10 μl to degrade genomic DNA, according to the manufacturer’s instruc-
tions. 1 μl of this treated RNA solution was reverse transcribed with 200 U 
SuperScript II Reverse Transcriptase (Invitrogen) according to the manu-
facturer’s instructions using 250 ng random hexamers in a total volume of 
21.1 μl. qPCR reactions were performed on the equivalent of 1.6 ng of input 
RNA using Power SYBR Green PCR Master Mix (Applied Biosystems) and 
20 μM of each oligonucleotide in a 25-μl reaction on a Stratagene Mx3005P 
thermocyler using the following cycling parameters: 10 minutes at 95°C fol-
lowed by 40 cycles of 30 seconds at 95°C, 1 minute at 55°C, and 1 minute 
at 72°C. Oligonucleotide sequences for Gdnf, Ece1 (60), and Gapdh (61) were 
described previously, and sequences for Edn3 were 5′-TCACCAGTTATTC-
CGGGAGAG-3′ and 5′-TAAGGCCGGTGGGCTTTATC-3′. No-template 
controls and no-RT enzyme controls were performed for each primer pair. 
3 replicate reactions were run for each sample-amplicon combination, and 
average PCR efficiencies for each amplicon were calculated using LinReg-
PCR software (62), which were then used to calculate efficiency-corrected 
fold changes (63) using Gapdh as a reference gene.
Microscopy and quantification. Micrographs were acquired with Olympus 
BX60 or IX71 microscopes, Axiocam CCD camera, and Axiovision software 
or with an Olympus FV1000 confocal microscope and Fluoview software. 
ImageJ was used for image processing, which was limited to cropping, 
stitching multiple fields (64), rotating, and uniform contrast adjustments. 
Confocal micrographs are presented as single optical sections or maxi-
mum-intensity projections.
Uncolonized zebrafish bowel was measured using micrometer-calibrated 
gridded eyepieces. Mouse bowel colonization was measured with ImageJ. 
E18.5 bowel was considered hypoganglionic when gaps between myen-
teric ganglia became perceptibly larger and ganglia contained fewer neu-
rons. For explant cultures, we measured the distance between gut edges 
and cell bodies of the most distant ENCDC in 8 sectors per explant. In 
X-inactivation mosaic experiments, overall, EGFP+, and EGFP– migration 
were measured. Time-lapse images were acquired every 3 minutes on an 
AxioObserver.Z1 microscope (Zeiss) equipped with motorized stage, incu-
bator, and CO2 controller. Cells were tracked with MTrackJ software (65).
rich Alexander University Erlangen Nuremberg, Erlangen, Germany, and 
M. Southard-Smith, Vanderbilt University, Nashville, Tennessee, USA), and 
Ret9 (hypomorphic allele Rettm2(RET)Jmi; provided by S. Jain, Washington Uni-
versity School of Medicine, St. Louis, Missouri, USA; ref. 38) backcrossed 
to 129X1 for 2–5 generations. Wnt1-Cre Rosa26EYFP/EYFP and Hprt– (Hprtb-m3; 
provided by B.S. Mitchell, Stanford University, Stanford, California, 
USA; ref. 28) mice were on a mixed background. PCR genotyping (58) for 
Sox10LacZ and Wnt1-Cre used previously published primers (58); other 
primers are listed in Supplemental Table 3.
MPA and MMF treatment. Dams were injected daily with MPA (Sigma- 
Aldrich; catalog no. M3536) in DMSO or with DMSO alone (1.24 μl/g 
body weight, 31.25–250 mM MPA, intraperitoneal) or given prodrug MMF 
(Accord Healthcare, NDC catalog no. 16729-094) at 1 mg/ml in 0.25× PBS 
adjusted to pH 3.6 as drinking water (23). MMF and PBS groups drank 
equal amounts. Cardiovascular anatomy at E18.5 was visualized under a 
dissection stereomicroscope by left ventricle injection with India ink (Wind-
sor Newton) diluted 1:10 in water.
Primary ENCDC culture. 300- to 500-μm slices of E12.5 small bowel were 
cultured on fibronectin-coated (250 μg/ml; Invitrogen) Lab-Tek Permanox 
chamber slides (Thermo Fisher) in DMEM (high glucose), 200 mM l-glu-
tamine, 100 IU/ml penicillin, 100 g/ml streptomycin, 1× B-27 supplement 
(Invitrogen), and MPA in DMSO (0.01% final concentration). At 4 hours 
after plating, 50 ng/ml GDNF (59) was added to trigger migration. Cul-
tures were maintained for an additional 16 or 24 hours (37°C, 5% CO2). 
When appropriate, 10 μM BrdU was added 5 hours before fixation. All 
culture experiments not involving mutant mice used CF1 fetuses. Sox10, 
Ret, and Hprt fetuses were cultured individually and genotyped.
For measuring neurite length, E12.5 bowel was enzymatically dissoci-
ated into a single-cell suspension (22), and cells were cultured in neuro-
basal media supplemented with 1× B-27, 200 mM l-glutamine, 100 IU/ml 
penicillin, and 100 g/ml streptomycin. Cultures were plated at a density of 
1,250 cells/cm2 on glass chamber slides (Lab-Tek) coated with poly-d-lysine 
(100 μg/ml; Sigma-Aldrich) and laminin (BD Biosciences) and cultured for 
48 hours before fixation. BrdU (10 μM), DMSO or MPA (5 μM final), and 
GDNF (50 ng/ml) were added at plating. For time-lapse EYFP microscopy, 
E12.5 Wnt1-Cre Rosa26EYFP/+ midguts were cultured as dissociated cells or 
slices as described above and plated on fibronectin-coated glass chamber 
slides (Thermo Fisher). Both cells and slices were cultured in phenol red–free 
DMEM supplemented with B-27, l-glutamine, and antibiotics as described 
above. All other culture conditions were identical to those of explant cultures.
X-inactivation mosaic analysis. X-EGFP+ male mice were bred to Hprt+/– 
females. E12.5 midgut explants resulting from these matings (X-EGFP+, 
Hprt+/–) were cultured for 16 hours in the presence of both MPA (5 μM) 
and guanosine (100 μM) to rescue all WT cells while GTP-depleting all 
cells that do not express HPRT. Since both Hprt and the EGFP transgene 
are subject to mosaic X-inactivation, in Hprt+/– explants, EGFP marks WT 
(rescued) cells but not mutant (depleted) cells. EGFP expression from the 
transgene was weak, and visualization required immunohistochemistry.
Immunohistochemistry. Zebrafish were fixed and then stained in whole-
mount as previously described (19) with anti-HuC/HuD monoclonal 
16A11 (250 ng/ml; Invitrogen) and Alexa Fluor 594 anti-mouse secondary 
(1:250; Invitrogen) antibodies before mounting in 50% glycerol/PBS.
E18.5 mouse bowel flushed with PBS was fixed (4% paraformaldehyde 
in PBS for 30 minutes at 25°C), washed in PBS, and then permeabilized/
blocked for 1 hour at 25°C in TBST (Tris-buffered saline with 0.1% Triton-X 
100), 1% cold water fish skin gelatin (Sigma-Aldrich), 100 mM glycine, and 
5% normal serum matching secondary species (Jackson Immuno Research). 
Primary antibodies (Supplemental Table 4) were incubated overnight in 
blocking solution at 4°C. Fluorophore-conjugated secondary antibody 
(Alexa Fluor 488 donkey anti-rabbit, Alexa Fluor 594 donkey anti-rabbit, 
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All experiments were performed in at least triplicate with separate 
embryos or separate pools of embryos in culture. For drug-treated preg-
nant mice, at least 3 litters were collected per treatment. Mean ± SEM are 
plotted unless otherwise indicated. Analyses were performed by observers 
blind to genotype and treatment status.
Statistics. We used SigmaPlot 11 (Systat Software) or R (R Foundation) 
for analysis. For fetal bowel colonization, Student’s t test or 1-way ANOVA 
was used. For WT explants, repeated-measures ANOVA was used unless 
otherwise indicated. For mutant explants, 2-way ANOVA was used to test 
influence of genotype, treatment, and interactions. Paired t tests or Wil-
coxon signed-rank tests (when data were non-normally distributed) were 
used for mosaic analyses. Other parameters were compared with 1-way 
ANOVA, t test, rank-sum test, or Kolmogorov-Smirnov test as indicated. 
For all analyses, P < 0.05 was considered significant, and 2-tailed tests 
were performed. P values were adjusted for multiple comparisons by the 
Holm-Bonferroni procedure based on numbers of planned comparisons. 
When colonization was normalized to bowel length, absolute length of 
aganglionic (or abnormal) segments were also tested and always agreed 
with the normalized results.
Study approval. Animal experiments were approved by the Washington 
University Animal Studies Committee.
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